Get the Stockscreener App
16.24
2.53%
0.40
Syndax Pharmaceuticals Inc stock is traded at $16.24, with a volume of 1.47M.
It is up +2.53% in the last 24 hours and up +57.52% over the past month.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
See More
Previous Close:
$15.84
Open:
$15.97
24h Volume:
1.47M
Relative Volume:
0.66
Market Cap:
$1.40B
Revenue:
$139.71M
Net Income/Loss:
$-209.36M
P/E Ratio:
-5.4865
EPS:
-2.96
Net Cash Flow:
$-160.60M
1W Performance:
+3.18%
1M Performance:
+57.52%
6M Performance:
-0.85%
1Y Performance:
-20.08%
1-Day Range:
$15.81
$16.38
1-Week Range:
$15.36
$16.38
52-Week Range:
$8.58
$22.50
Syndax Pharmaceuticals Inc Stock (SNDX) Company Profile
Name
Syndax Pharmaceuticals Inc
Sector
Industry
Phone
781-419-1400
Address
730 THIRD AVENUE, NEW YORK, MA
Compare SNDX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SNDX
Syndax Pharmaceuticals Inc
|
16.24 | 1.37B | 139.71M | -209.36M | -160.60M | -2.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Syndax Pharmaceuticals Inc Stock (SNDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-05-25 | Reiterated | BTIG Research | Buy |
| Jul-10-25 | Initiated | Goldman | Buy |
| Oct-24-24 | Initiated | UBS | Buy |
| Jun-28-24 | Initiated | Jefferies | Buy |
| Jan-31-24 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| Dec-22-23 | Initiated | Mizuho | Buy |
| Oct-25-23 | Initiated | BofA Securities | Buy |
| Oct-11-23 | Initiated | Goldman | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Outperform |
| Jul-11-23 | Initiated | Guggenheim | Buy |
| Apr-17-23 | Resumed | BTIG Research | Buy |
| Jan-31-23 | Initiated | Stifel | Buy |
| Jan-03-23 | Initiated | JP Morgan | Overweight |
| Jul-28-22 | Resumed | B. Riley Securities | Buy |
| Apr-11-22 | Initiated | H.C. Wainwright | Buy |
| Feb-15-22 | Initiated | Goldman | Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| May-25-21 | Initiated | Citigroup | Buy |
| Feb-18-21 | Initiated | B. Riley Securities | Buy |
| Dec-03-20 | Initiated | Stifel | Buy |
| May-22-20 | Upgrade | Citigroup | Neutral → Buy |
| May-22-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-18-20 | Downgrade | Citigroup | Buy → Neutral |
| May-11-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-13-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-08-19 | Reiterated | H.C. Wainwright | Buy |
| Jan-04-19 | Initiated | Robert W. Baird | Outperform |
| Jan-05-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Mar-16-17 | Initiated | FBR & Co. | Outperform |
| Mar-02-17 | Initiated | Instinet | Buy |
| Oct-07-16 | Initiated | Guggenheim | Buy |
| Mar-28-16 | Initiated | Citigroup | Buy |
| Mar-28-16 | Initiated | JMP Securities | Mkt Outperform |
| Mar-28-16 | Initiated | Morgan Stanley | Overweight |
View All
Syndax Pharmaceuticals Inc Stock (SNDX) Latest News
Dennis Podlesak Sells 19,200 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Stock - MarketBeat
Syndax Pharmaceuticals (NASDAQ:SNDX) Trading 4.4% HigherHere's What Happened - MarketBeat
Algert Global LLC Raises Stake in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Regulatory Milestone and Analyst Optimism Fuel Momentum for Syndax Pharmaceuticals - MSN
Aigen Investment Management LP Invests $297,000 in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
What MACD and RSI say about Syndax Pharmaceuticals Inc.Earnings Overview Summary & Consistent Growth Stock Picks - Newser
Syndax Pharmaceuticals Director Podlesak Dennis Makes Large Trades in August 2025 - AInvest
Syndax signals $4B total market opportunity with Revuforj expansion into frontline settings - MSN
BTIG Raises Syndax Pharmaceuticals (SNDX) PT to $56 Following Strong Q2 Revenue from Revuforj, Niktimvo - Yahoo Finance
Syndax Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:SNDX) - MarketBeat
Published on: 2025-08-17 17:19:16 - theviewers.co.kr
Why Syndax Pharmaceuticals Inc. stock attracts strong analyst attention2025 Historical Comparison & Weekly Top Gainers Alerts - thegnnews.com
Syndax jumps after Q2 beat; Citi issues upside catalyst watch - MSN
Will Syndax Pharmaceuticals Inc. outperform tech stocksJuly 2025 Setups & Capital Efficiency Focused Ideas - sundaytimes.kr
Can Syndax Pharmaceuticals Inc. deliver consistent dividendsJuly 2025 Selloffs & Fast Moving Market Watchlists - thegnnews.com
Syndax Pharmaceuticals (SNDX): A Sustainable Growth Story or a Market Overreaction? - AInvest
Syndax Pharmaceuticals (SNDX) Is Up 15.8% After Revenue Surges in Q2 2025 Results Has Sentiment Shifted? - Yahoo Finance
Syndax Skyrockets 8.58%—Is This the Start of a Biotech Breakout? - AInvest
Does Syndax (SNDX) Have the Potential to Rally 158.36% as Wall Street Analysts Expect? - Zacks Investment Research
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Syndax Pharmaceuticals: A Tale of Two Drug Launches - AInvest
Syndax Pharmaceuticals: A Tale Of Two Drug Launches (NASDAQ:SNDX) - Seeking Alpha
FDA Priority Review and Revenue Growth Drive Short-Term Upswing for Syndax Pharmaceuticals - Insider Monkey
Syndax Pharmaceuticals' Path to Blockbuster Status: Leveraging FDA Priority Review and Revenue Growth in Oncology - AInvest
Analysts Set Expectations for SNDX Q3 Earnings - MarketBeat
S&E In Brief: Launch Updates And Political Headwinds - insights.citeline.com
What makes Syndax Pharmaceuticals Inc. stock price move sharplyLow Cost High Gain Picks - mustnews.co.kr
Syndax Pharmaceuticals (NASDAQ:SNDX) Upgraded by B. Riley to Strong-Buy Rating - MarketBeat
Analysts Just Made A Massive Upgrade To Their Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Forecasts - 富途牛牛
Analysts Boost Syndax Pharmaceuticals' Forecasts, Revenue and EPS Estimates Increase - AInvest
Analysts Just Made A Dazzling Upgrade To Their Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Forecasts - Yahoo Finance
11 Best Short-Term Stocks to Invest in - Insider Monkey
Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Gap Up on Better-Than-Expected Earnings - MarketBeat
Syndax Pharmaceuticals Publishes Positive Revumenib Data from BEAT AML Trial - MSN
BTIG Research Forecasts Strong Price Appreciation for Syndax Pharmaceuticals (NASDAQ:SNDX) Stock - MarketBeat
Syndax Pharmaceuticals (NASDAQ:SNDX) Issues Quarterly Earnings Results, Beats Estimates By $0.18 EPS - MarketBeat
Citi Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Announces Target Price $51 - 富途牛牛
Citi Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Maintains Target Price $51 - 富途牛牛
XTX Topco Ltd Invests $783,000 in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Syndax targets expanded $10B market opportunity with Revuforj and Niktimvo amid accelerating adoption and guidance for stable expenses - MSN
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
Syndax Pharmaceuticals Announces Inducement Stock Grants Under NASDAQ Listing Rule 5635(c)(4) - AInvest
Syndax Pharmaceuticals Inc Stock (SNDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Syndax Pharmaceuticals Inc Stock (SNDX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Podlesak Dennis | Director |
Aug 15 '25 |
Option Exercise |
7.20 |
19,200 |
138,240 |
210,963 |
| Podlesak Dennis | Director |
Aug 18 '25 |
Option Exercise |
7.20 |
19,200 |
138,240 |
210,963 |
| Podlesak Dennis | Director |
Aug 18 '25 |
Sale |
15.84 |
19,200 |
304,170 |
191,763 |
| Podlesak Dennis | Director |
Aug 15 '25 |
Sale |
15.54 |
19,200 |
298,408 |
191,763 |
| Podlesak Dennis | Director |
Aug 14 '25 |
Sale |
14.19 |
19,200 |
272,521 |
191,763 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):